0.3239
price up icon6.20%   0.0189
after-market Handel nachbörslich: .35 0.0261 +8.06%
loading
Schlusskurs vom Vortag:
$0.305
Offen:
$0.286
24-Stunden-Volumen:
3.91M
Relative Volume:
2.20
Marktkapitalisierung:
$70.66M
Einnahmen:
$175.04M
Nettoeinkommen (Verlust:
$-44.52M
KGV:
-1.7994
EPS:
-0.18
Netto-Cashflow:
$-56.05M
1W Leistung:
+47.23%
1M Leistung:
-36.58%
6M Leistung:
-63.81%
1J Leistung:
-76.53%
1-Tages-Spanne:
Value
$0.2666
$0.3301
1-Wochen-Bereich:
Value
$0.1951
$0.3301
52-Wochen-Spanne:
Value
$0.1951
$1.48

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name
Firmenname
Adaptimmune Therapeutics Plc Adr
Name
Telefon
44 1235 430000
Name
Adresse
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Name
Mitarbeiter
506
Name
Twitter
@Adaptimmune
Name
Nächster Verdiensttermin
2025-03-21
Name
Neueste SEC-Einreichungen
Name
ADAP's Discussions on Twitter

Vergleichen Sie ADAP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ADAP
Adaptimmune Therapeutics Plc Adr
0.3239 70.66M 175.04M -44.52M -56.05M -0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 125.55B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 67.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 36.24B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.99B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.77B 3.81B -644.79M -669.77M -6.24

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-30 Eingeleitet H.C. Wainwright Buy
2024-05-30 Eingeleitet Scotiabank Sector Outperform
2023-03-24 Eingeleitet Bryan Garnier Buy
2023-01-03 Hochstufung Guggenheim Neutral → Buy
2022-11-09 Hochstufung Mizuho Neutral → Buy
2021-05-28 Eingeleitet Barclays Underweight
2020-04-22 Eingeleitet Mizuho Neutral
2019-08-02 Herabstufung Guggenheim Buy → Neutral
2019-05-31 Eingeleitet ROTH Capital Buy
2019-05-30 Fortgesetzt Citigroup Buy
2019-05-07 Herabstufung SVB Leerink Outperform → Mkt Perform
2017-03-17 Eingeleitet Wells Fargo Market Perform
2016-10-24 Herabstufung BofA/Merrill Neutral → Underperform
2016-09-30 Eingeleitet Raymond James Outperform
2016-02-25 Eingeleitet Citigroup Buy
2015-06-01 Eingeleitet BofA/Merrill Neutral
2015-06-01 Eingeleitet Guggenheim Buy
2015-06-01 Eingeleitet Leerink Partners Outperform
Alle ansehen

Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten

pulisher
Apr 02, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com

Apr 02, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India

Apr 01, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com India

Mar 26, 2025
pulisher
Mar 24, 2025

Adaptimmune Therapeutics Amends Loan Agreement - Investing.com India

Mar 24, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com

Mar 21, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com

Mar 20, 2025
pulisher
Mar 06, 2025

Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Feb 25, 2025

LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025
pulisher
Feb 25, 2025

Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register

Feb 25, 2025
pulisher
Feb 19, 2025

Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily

Feb 19, 2025
pulisher
Feb 12, 2025

Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily

Feb 12, 2025
pulisher
Feb 11, 2025

Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex

Feb 11, 2025
pulisher
Feb 08, 2025

Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 07, 2025

Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

SM Energy Co (SM): A Technical Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 04, 2025

Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex

Feb 04, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 16, 2025

Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India

Jan 16, 2025
pulisher
Jan 15, 2025

Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com

Jan 15, 2025
pulisher
Jan 15, 2025

Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com

Jan 15, 2025
pulisher
Dec 23, 2024

AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock ‎Is - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register

Dec 23, 2024
pulisher
Dec 16, 2024

Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com

Dec 16, 2024
pulisher
Dec 04, 2024

Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com

Dec 04, 2024
pulisher
Dec 02, 2024

Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail

Dec 02, 2024
pulisher
Nov 27, 2024

Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com

Nov 27, 2024
pulisher
Nov 18, 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

Nov 18, 2024
pulisher
Nov 18, 2024

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

Nov 18, 2024
pulisher
Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024
pulisher
Nov 05, 2024

ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 01, 2024

Adaptimmune faces Nasdaq delisting over share price - Investing.com India

Nov 01, 2024

Finanzdaten der Adaptimmune Therapeutics Plc Adr-Aktie (ADAP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):